Umoja Biopharma stock

Umoja Biopharma Stock

HealthTech

Looking to sell Umoja Biopharma stock or options?

Contact us
Founded: 2019Funding to Date: $274M
Visit website

Umoja Biopharma is a provider of advanced immunotherapies designed to revolutionize cancer treatment and enhance patient quality of life. The company's innovative cellular immunotherapy platform employs gene therapy to specifically target cancer cells. This platform can be delivered to any patient, with any type of tumor, at any given time. It works by directly, safely, and controllably attacking cancer, which empowers healthcare professionals to protect patients by generating and harnessing a robust immune response within the body.

Investors Include:

Presight Capital, RTW Investments, MPM BioImpact, Seattle Children's Hospital, Emerson Collective, Casdin Capital, WRF Capital, Cormorant Asset Management, SoftBank Investment Advisers, CaaS Capital Management, Temasek Holdings, Alexandria Venture Investments, Purdue Ventures, Qiming Venture Partners USA, Leerink Partners, DCVC Bio.